Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241796 · ClinicalTrials.gov registry record · NA
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
A NA study, sponsored by GRAIL.
- Completed
- Registry status
- NA
- Development phase
- 6,662
- Enrollment target
NCT04241796 is a NA study that has completed, run by GRAIL. The registered enrollment target is 6,662 participants.
The verdict
NCT04241796, a NA study, has completed, sponsored by GRAIL.
- COMPLETED
- Registry status
- NA
- Development phase
- 6,662 participants
- Enrollment target
Study Summary
PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a predicted or indeterminate tissue of origin (TOO)), the diagnostic work-up will not be dictated by the protocol, but will instead be coordinated by the ordering and treating medical team at the enrolling sites based on the participant's clinical condition, recommendations by each institution's clinical practices, and in consultation with the study investigator and interdisciplinary care team, as necessary. Additionally, proposed clinical care pathways, developed based on a review of guidelines from the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR) and other professional organizations, should be referenced by the medical team to determine the diagnostic work-up. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Performance of multi-cancer early detection test will be evaluated. Additionally, participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test. Participants will be followed for approximately 12 months from the time of enrollment. Cancer status will also be assessed at the 12 month time point.
Interventions
- DEVICE Multi-Cancer Early Detection Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,662 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2022-01-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04241796
The ClinicalTrials.gov registry entry for NCT04241796 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6,662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GRAIL, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multi-Cancer Early Detection Test is the first listed.
NCT04241796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04241796 about?
NCT04241796 is a clinical study titled "Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice". PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a...
What is the current status of trial NCT04241796?
This trial is currently completed. It is a NA study. The enrollment target is 6,662 participants. The study started on 2019-12-12. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT04241796?
The interventions under investigation include: Multi-Cancer Early Detection Test (DEVICE).
Who is sponsoring clinical trial NCT04241796?
This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.